Latest Breaking News On - எக்ஷெலிக்ஷிச் இன்க் - Page 3 : vimarsana.com

(2) Regulatory News: Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC) met one of the primary endpoints, demonstrating significant improvement in progression-free survival (PFS) at the planned primary analysis. A prespecified interim analysis for the second primary endpoint of overall survival (OS), conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination of cabozantinib and atezolizumab, but did not reach statistical significance. Based on the preliminary OS data, Exelixis anticipates that the probability of reaching statistical significance at the time of the final analysis is low. The trial will continue as planned to the final analysis of OS; results are anticipated in early 2022.

France generalUnited statesHong kongUnited kingdomNew zealandSouth koreaUnited arab emiratesDominican republicSaudi arabiaRussian federationSusan hubbardMichaelm morrisseyLindsay treadwayGemma roperIpsen euronextDaiichi sankyo company